Literature DB >> 1958085

Connective tissue disease in patients presenting with Raynaud's phenomenon alone.

C G Kallenberg1.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 1958085      PMCID： PMC1004524          DOI： 10.1136/ard.50.10.666

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  16 in total

1.  Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire.

Authors:  H R Maricq; M C Weinrich; J E Keil; E C LeRoy
Journal:  J Chronic Dis       Date:  1986

2.  Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.

Authors:  D D Gerbracht; V D Steen; G L Ziegler; T A Medsger; G P Rodnan
Journal:  Arthritis Rheum       Date:  1985-01

3.  Scl-86, a marker antigen for diffuse scleroderma.

Authors:  W J van Venrooij; S O Stapel; H Houben; W J Habets; C G Kallenberg; E Penner; L B van de Putte
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

4.  Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon.

Authors:  C G Kallenberg; A A Wouda; T H The
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

5.  A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report.

Authors:  F E Harper; H R Maricq; R E Turner; R W Lidman; E C Leroy
Journal:  Am J Med       Date:  1982-06       Impact factor: 4.965

6.  Decreased nailfold capillary density in Raynaud's phenomenon: a reflection of immunologically mediated local and systemic vascular disease?

Authors:  P M Houtman; C G Kallenberg; A A Wouda; T H The
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

7.  Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders.

Authors:  H R Maricq; E C LeRoy; W A D'Angelo; T A Medsger; G P Rodnan; G C Sharp; J F Wolfe
Journal:  Arthritis Rheum       Date:  1980-02

8.  Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis.

Authors:  H R Maricq; G Spencer-Green; E C LeRoy
Journal:  Am J Med       Date:  1976-12       Impact factor: 4.965

9.  Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease.

Authors:  H Groen; G Wichers; E J ter Borg; T W van der Mark; A A Wouda; C G Kallenberg
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

10.  Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.

Authors:  C G Kallenberg; G W Pastoor; A A Wouda; T H The
Journal:  Ann Rheum Dis       Date:  1982-08       Impact factor: 19.103
View more
  3 in total

Review 1.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

2.  Late appearance and exacerbation of primary Raynaud's phenomenon attacks can predict future development of connective tissue disease: a retrospective chart review of 3,035 patients.

Authors:  Slavica Pavlov-Dolijanovic; Nemanja S Damjanov; Nada Z Vujasinovic Stupar; Goran L Radunovic; Roksanda M Stojanovic; Dragan Babic
Journal:  Rheumatol Int       Date:  2012-07-22       Impact factor: 2.631

Review 3.  Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.

Authors:  Marta Cossu; Lorenzo Beretta; Petra Mosterman; Maria J H de Hair; Timothy R D J Radstake
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.